Rare Kidney Diseases Market

Market Size

The global rare kidney diseases market size, valued at USD 3.4 billion in 2025, is projected to reach USD 4.9 billion in 2026 and USD 21.7 billion by 2040, with a CAGR of 11.2% during the forecast period 2026 to 2040.

Market Report: Key Takeaways

• In terms of target indication, immunoglobulin A nephropathy holds majority of the current rare kidney diseases market, driven by rising disease prevalence, the approval of targeted therapies, and strong clinical trial activity in the domain.
• Small molecules capture the largest share (more than 60%) of the overall rare kidney diseases market, owing to their proven efficacy along with their ease of administration, lower production costs and established safe drug profiles.
• In terms of type of biologic, monoclonal antibodies capture the largest share of the current rare kidney diseases market as a result of the high target specificity and proven precision to treat rare kidney indications.
• The oral route of administration currently captures the largest share (nearly 65%) of the rare kidney diseases market due to its non-invasive nature, convenience of drug administration and increased patient compliance.
• In terms of type of therapy, monotherapies occupy a greater share of the rare kidney diseases market. Recent studies, though, have shown that combination therapies can be an effective alternative in patients with chronic kidney disease for whom other therapies are not effective.
• North America holds nearly 60% of the rare kidney diseases market value. The market in Asia-Pacific is likely to grow at a relatively faster pace during the forecast period.

Key Market Statistics

• Market Size in 2026: $4.9 Billion
• Estimated Market Size in 2040: $21.7 Billion
• CAGR (2026-2040): 11.2%
• North America: Largest market in 2026
• Asia-Pacific: Fastest growing region

Market Overview

Kidney diseases are a set of conditions that hinder the kidney’s natural ability to efficiently filter fluid and waste from the blood. These diseases also lower the ability of the kidneys to regulate blood pressure and maintain overall fluid balance in the body. In the early stages, these diseases often do not reflect any symptoms, hence making it difficult to diagnose. As waste builds up in the body, patients may report symptoms, such as high blood pressure, anemia, poor nutritional health and nerve damage.

According to the US Chronic Kidney Disease Surveillance program, about 37 million people in the US are estimated to be suffering from chronic kidney disease, accounting for approximately 14% of the overall population in the US. Rare kidney diseases are a subset of kidney diseases, which affect only a small fraction of people worldwide. According to the Orphan Drug Act, in the United States, diseases are considered rare when they affect less than 200,000 Americans. However, according to the European Union, the prevalence threshold is 5 per 10,000 people., ,

These diseases primarily affect the filtering units (known as glomeruli), present in the kidneys, which result in the spillage of protein components and blood into the urine. Considering that these diseases can either be congenital, acquired or inherited in nature, it is highly difficult to identify biomarkers for their diagnosis and treatment. If these conditions do not receive timely treatment, they ultimately result in kidney failure and can, subsequently, only be managed through dialysis and kidney transplantation. Kidney failure due to a rare chronic kidney disease has been observed to be prevalent in at least 3 in 5 children and 1 in 9 adults suffering from kidney diseases. This growing burden of rare kidney disorders is prompting industry stakeholders, including pharmaceutical companies and biotech firms, to accelerate the development of targeted therapies and orphan drugs specifically designed to address these underserved conditions. Across related applications, complement inhibitors block dysregulated complement activation implicated in neurological, hematological and renal diseases.

Rare Kidney Diseases Market Trends

• Partnerships and Collaborations: Several rare kidney disease companies have recently pursued partnerships to strengthen their market position. Product licensing emerged as the most prominent partnership model, closely followed by acquisitions. Companies undertake such collaborations to rapidly expand clinical and commercial capabilities, lower development risks, and bypass heavy internal investment. Through these alliances, they immediately access their partners’ regulatory expertise, manufacturing capacity, and established market channels.
• Clinical Trials Analysis: Since 2020, researchers have launched or completed nearly 405 clinical trials for rare kidney diseases, signaling strong industry momentum. Interestingly, over 30% of these trials were registered in 2025, reflecting surging interest among researchers and drug developers in the development of novel therapies. Asia-Pacific currently leads the clinical trial landscape, hosting majority of the ongoing and completed trials.

Scope, Methodology and Industry Experts Interviews

Roots Analysis segments the rare kidney diseases by target indication, type of molecule, type of biologic, route of administration, type of therapy, geographical regions, and leading drug developers.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders across the rare kidney diseases domain. These discussions informed the assessment of disease diagnosis and treatment pathways, unmet clinical needs, drug development activity, patient identification and recruitment challenges, treatment adoption, partnership activity, funding, regulatory considerations, reimbursement dynamics, and commercial opportunities. The market report includes detailed transcripts of the following third-party discussions:

• Founder and Chief Executive Officer, Mid-Sized Company, US
• President and Chief Executive Officer, Mid-Sized Company, US
• President and Chief Executive Officer, Mid-Sized Company, Israel
• Executive Director, Strategic Relations, Small Sized Non-Profit Organization, US
• Associate BD Director, Very Large Company, China
• Nephrologist, Very Large Clinic, UK; Nephrologist, Large Hospital, UK
• Nephrologist, Medical Director, Mid-Sized Company, United States; Professor of Medicine, Very Large University, US; Associate Professor, Very Large University, US
• Professor of Nephrology and Chair of Nephrology, Very Large University, US
• Professor of Medicine, Very Large University, Belgium

Commenting on this Chris Gisler, Nephrologist, Medical Director, Travere Therapeutics states, “The future of rare kidney disease treatment paradigm is likely to involve multi-pathway treatment strategies. Moreover, combination therapies targeting different biological mechanisms may provide greater disease control than single-therapy options.”

Market Drivers

• Rising Incentives by Regulatory Agencies: Regulatory incentives such as Orphan Drug and Fast-Track designations are accelerating market entry for rare kidney disease therapies by shortening development timelines, enabling priority review, and offering extended market exclusivity. These designations reduce investment risk, attract the interest of biopharmaceutical companies, and encourage strategic partnerships, collectively driving innovation, commercial viability, and faster patient access in the rare kidney diseases market.
• Advances in Biomarker Discovery and Genetic Screening: Advances in genetic testing and biomarker discovery are improving detection of inherited kidney disorders (such as Fabry disease), enabling earlier and more accurate diagnoses. Timely identification accelerates patient enrollment in clinical trials, facilitates personalized treatment strategies, and supports targeted drug development. Together, these trends increase demand for specialized therapies and expand market opportunities in the rare kidney disease industry.

Market Segmentation Analysis

Immunoglobulin A Nephropathy Leading the Rare Kidney Diseases Market

Immunoglobulin A nephropathy holds nearly 40% of the overall rare kidney diseases market share and is likely to remain dominant during the forecast period. This is a result of the increasing incidence and improved diagnosis rates of the disease, along with the availability of newly approved targeted therapies and a strong pipeline of ongoing clinical trials. Governments and healthcare providers are also placing greater emphasis on early intervention for immunoglobulin A nephropathy to mitigate the substantial long-term economic burden associated with dialysis and kidney transplants, further driving investment and development in this area.

Market Regional Insights

North America Dominates the Overall Market

North America dominates the market for rare kidney diseases, securing nearly 60% of the overall revenue share, due to strong research and development, high concentration of biotechnology companies, and a favorable regulatory environment for orphan drugs in the US. These factors support pharmaceutical drug development pipelines and accelerate commercialization as compared to other regions.

Emerging Opportunities in Rare Kidney Diseases Market

Precision Combination Therapies for Rare Kidney Diseases Guided by Molecular Profiling

Combination therapies and personalized medicine are converging to create a transformative opportunity in the rare kidney disease drug market, as targeted combination regimens enable simultaneous modulation of multiple disease pathways while individualized molecular profiling helps optimize therapeutic selection and dosing for each patient. By integrating genomic (genes), protein, and clinical biomarkers, developers can effectively identify patients within diverse patient populations, reduce trial sizes, and accelerate regulatory acceptance through better benefit signals. Payers and health systems are increasingly recognizing the long-term value of precision approaches, which help lower long-term morbidity and healthcare costs. This recognition is driving greater investment, collaborative trials, and adaptation of regulatory pathways, collectively de-risking development and accelerating patient access to novel kidney therapies.

Rare Kidney Diseases Market: Scope of the Report

Market Segments

Based on the research, we have segmented the Rare Kidney Diseases Market into target indication, type of molecule, type of biologic, route of administration, type of therapy, and geographical regions.

By Target Indication

• Immunoglobulin A Nephropathy, Lupus Nephritis, Atypical Hemolytic Uremic Syndrome, Fabry Disease, Focal Segmental Glomerulosclerosis, Complement 3 Glomerulopathy, Hepatorenal Syndrome, Immune Complex-Mediated Membranoproliferative Glomerulonephritis, Distal Renal Tubular Acidosis, Membranous Nephropathy, and Nephrotic Syndrome

By Type of Molecule

• Small Molecules and Biologics

By Type of Biologic

• Monoclonal Antibodies, Enzymes, Proteins / Peptides, Hormones, and Cell / Gene Therapies

By Route of Administration

• Oral Route, Intravenous Route, and Subcutaneous Route

By Type of Therapy

• Monotherapies and Combination Therapies

By Geographical Regions

• North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa

By Leading Drug Developers

Key Players

The report profiles Advicenne, Alexion Pharmaceuticals, Amgen, Asahi Kasei, Biogen, Boehringer Ingelheim, Calliditas Therapeutics, Jiangsu Hengrui Pharmaceuticals, Novartis, NovelMed, Roche, Travere Therapeutics, Vertex Pharmaceuticals, Vera Therapeutics, and ZyVersa Therapeutics.

Report Authorship

This report was authored by Simriti Gupta, member of Roots Analysis healthcare and pharmaceutical research practice. Her work focuses on drug development and manufacturing, competitive intelligence, company benchmarking and market forecasting.

Independence and Non-Affiliation

Roots Analysis is an independent secondary and primary market research publisher. This report is not affiliated with, endorsed by, or produced on behalf of any company named or profiled within it, including all key players and industry expert interviewees referenced above.

Roots Analysis' findings draw on a combination of secondary research and primary interviews with industry experts, of the kind referenced above, to validate market sizing, segment shares, and forecast assumptions independently of any single company's disclosures.

Frequently Asked Questions